A push to license cancer drugs in low-income countries; interview with FDA's top cancer regulator

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        STAT+: 'All about strengthening health systems': New coalition pushes to license cancer drugs to low-income countries By Ed Silverman Melissa Rendler-Garcia of UICC spoke with STAT about a new effort to license cancer drugs in low-income countries. Read More STAT+: Watch: An interview with the FDA's top cancer regulator By Matthew Herper FDA Rich Pazdur, the director of the FDA Oncology Center of Excellence, addressed rapid approvals, diversity in clinical trials, and more. Read More STAT+: Study suggests a new harm from hospital mergers: less price transparency By Tara Bannow Adobe A JAMA study highlights a new downside to hospital mergers: lower adherence to federal laws about price transparency. Read More Sponsor content by LASH GROUP Boost patient medication adherence with a digital companion Today's patients use smartphones and mobile apps like never before. That means endless opportunities to connect with them digitally to boost medication adherence and optimize outcomes. With the help of digital companion technology, you can elevate your patient support program. Download the Case Study to see how one manufacturer made medication management easier with digital engagement. 'Testing bottleneck' for monkeypox puts hope of containment at risk, experts warn By Helen Branswell and Andrew Joseph Pablo Blazquez Dominguez/Getty Images The CDC's two-step system is seen as not quick enough to help clinicians who should be actively looking for monkeypox infections. Read More Tuesday, June 7, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser